Business
AN2 Therapeutics to Participate at Upcoming Investor Conferences
MENLO PARK, Calif., February 20, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March.
About this update from An2 Therapeutics, Inc.
MENLO PARK, Calif., February 20, 2025 --( BUSINESS WIRE )--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45 th Annual Health Care Conference Leerink Partners Global Healthcare Conference A webcast of the Cowen Health Care Conference presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com . An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20250220323899/en/ Contacts COMPANY CONTACT: Lucy O. Day Chief Financial Officer [email protected] INVESTOR AND MEDIA CONTACT: Anne Bowdidge [email protected]
View stock analysis, news, and events for An2 Therapeutics, Inc.